Chemotherapy plus immunotherapy for patients with primary and metastatic brain tumors.
The authors report two clinical trials concerning chemotherapy and immunotherapy combined in the treatment of primary and metastatic brain tumors. In the first study bacillus Calmette-Guerin (BCG) and in the second Levamisole (LMS) were utilized as immunostimulating agents. Chemotherapy was performed with BCNU or CCNU in association with surgery and/or radiotherapy. The immunological response was obtained but immunotherapy failed to demonstrate any significant effect on survival.
D001254:Astrocytoma / Q000628:therapy; D001500:BCG Vaccine / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000556:secondary / Q000628:therapy*; D001943:Breast Neoplasms / Q000628:therapy; D002330:Carmustine / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D005260:Female; D005910:Glioma / Q000628:therapy; D006801:Humans; D007978:Levamisole / Q000627:therapeutic use*; D008130:Lomustine / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011379:Prognosis
D001500:BCG Vaccine; D007978:Levamisole; D008130:Lomustine; D002330:Carmustine